Evidence map›Paper›PMID 40551480›Full record

ArticleBritish journal of haematology2025

Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T.

Eugenio Galli, Roberta Di Blasi, Ilaria Pansini, Caterina Cristinelli, Come Bommier, Ilenia De Bernardis, Alessandro Corrente, Marcello Viscovo, Luca Montini, Patrizia Chiusolo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eugenio GalliDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-2839-916X
Roberta Di BlasiHemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.ORCID https://orcid.org/0000-0001-9001-573X
Ilaria PansiniHematology Section, Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Rome, Italy.ORCID https://orcid.org/0009-0008-8929-0361
Caterina CristinelliHemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.ORCID https://orcid.org/0000-0002-5757-3569
Come BommierHemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.ORCID https://orcid.org/0000-0002-5695-911X
Ilenia De BernardisHemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.
Alessandro CorrenteHematology Section, Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Marcello ViscovoDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0003-3012-6539
Luca MontiniDepartment of Anesthesia, Intensive Care, and Clinical Toxicology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0003-4602-5134
Patrizia ChiusoloDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-1355-1587
Stefan HohausDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-5534-7197
Federica SoràDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-9607-5298
Catherine ThieblemontHemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Louis Hospital, Paris, France.
Simona SicaDepartment of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0003-2426-3465

Funding

GITMO-Gruppo Italiano Trapianto Midollo OsseoItalian National Recovery and Resilience Plan (PNRR) MAD-2022-12376707Università Cattolica del Sacro Cuore
6 · The paper itself

Abstract

We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.

Indexed as

CAR‐Tcell therapynon‐Hodgkin‐S lymphomatolerability

Identifiers

PMID40551480
PMCPMC12378911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.